RA Capital Management portfolio · Q4 2025
RA Capital Management, L.P. · CIK 0001346824 ·13F filings on SEC EDGAR
In Q4 2025, RA Capital Management, L.P. reported 71 positions worth $9.8B. Its largest holding was 04351P101 at 22.5% of the portfolio, and the top 10 made up 66%. This is the earliest quarter available here, so changes are not shown.
Portfolio map
Each box is a position sized by its value. There is no previous quarter here to compare changes. The smallest 31 positions are grouped as one box.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
04351P101 ASCENDIS PHARMA A/S | 22.46% | $82.14* | $228.73 | +178.5% | $2.4B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CDTX CIDARA THERAPEUTICS INC | 7.62% | $38.25 | $220.89 | +477.5% | $743.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 7.31% | $39.80 | $95.22 | +139.3% | $634.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNAM AVIDITY BIOSCIENCES INC | 6.39% | $33.12 | $72.13 | +117.8% | $623.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 5.07% | $40.32 | $56.90 | +41.1% | $610.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 4.17% | $10.46 | $5.26 | -49.7% | $52.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 3.43% | $13.79 | $24.32 | +76.4% | $232.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 3.29% | $16.19 | $21.87 | +35.1% | $266.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Y95308105 WAVE LIFE SCIENCES LTD | 3.17% | $8.74* | $5.81 | -33.6% | $105.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 2.72% | $18.65 | $25.13 | +34.8% | $184M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 2.65% | $17.65 | $40.60 | +130.0% | $423.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 2.00% | $22.90 | $39.13 | +70.9% | $273.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 1.94% | $91.24 | $123.50 | +35.4% | $232.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 1.61% | $55.65 | $65.46 | +17.6% | $129.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 1.58% | $27.51 | $17.28 | -37.2% | $193.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 1.34% | $8.06 | $2.42 | -70.0% | $48.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 1.33% | $2.70 | $4.87 | +80.2% | $114.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 1.30% | $5.93 | $4.31 | -27.3% | $46.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 1.26% | $7.80 | $8.33 | +6.8% | $131.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 1.20% | $25.47 | $18.61 | -26.9% | $129.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 1.13% | $294.74 | $291.23 | -1.2% | $108.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GHRS GH RESEARCH PLC | 1.00% | $16.65 | $23.48 | +41.0% | $180.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.86% | $1.84 | $1.23 | -33.2% | $78.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACLX ARCELLX INC | 0.85% | $64.98 | $114.82 | +76.7% | $145.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 0.80% | $11.66 | $11.47 | -1.6% | $129.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOR VOR BIOPHARMA INC | 0.72% | $26.15 | $19.08 | -27.0% | $103.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLTE BELITE BIO INC - ADR | 0.71% | $74.00 | $169.82 | +129.5% | $73.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FULC FULCRUM THERAPEUTICS INC | 0.70% | $6.97 | $3.70 | -46.9% | $22.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LENZ LENZ THERAPEUTICS INC | 0.68% | $22.33 | $3.84 | -82.8% | $16M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNTH DIANTHUS THERAPEUTICS INC | 0.68% | $25.86 | $88.05 | +240.5% | $141.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OLMA OLEMA PHARMACEUTICALS INC | 0.67% | $25.00 | $8.64 | -65.4% | $22.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.61% | $17.12 | $8.26 | -51.8% | $28.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.58% | $13.86 | $14.05 | +1.4% | $51.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 0.54% | $32.76 | $89.03 | +171.8% | $144.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.51% | $9.93 | $3.38 | -66.0% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.50% | $17.05 | $38.38 | +125.0% | $84.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.45% | $32.12 | $79.67 | +148.0% | $53.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.45% | $28.86 | $37.88 | +31.3% | $57.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.43% | $9.26 | $14.31 | +54.6% | $80.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.43% | $1.10 | $0.87 | -20.9% | $14.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARTV ARTIVA BIOTHERAPEUTICS INC | 0.43% | $15.45 | $7.12 | -53.9% | $70.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 0.38% | $85.59 | $140.12 | +63.7% | $60M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.36% | $25.60 | $23.49 | -8.2% | $24M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 0.34% | $6.49 | $7.23 | +11.5% | $42M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.32% | $11.16 | $2.22 | -80.1% | $33.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTC BENITEC BIOPHARMA INC | 0.26% | $13.47 | $10.00 | -25.8% | $18.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.26% | $11.74 | $13.42 | +14.3% | $29.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.22% | $2.36 | $4.14 | +75.4% | $38M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRV ACRIVON THERAPEUTICS INC | 0.21% | $9.10 | $2.05 | -77.5% | $17.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTX NKARTA INC | 0.20% | $21.10 | $2.62 | -87.6% | $28.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.18% | $1.63 | $2.49 | +52.8% | $26.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.17% | $2.35 | $1.35 | -42.6% | $9.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.17% | $2.01 | $3.17 | +57.7% | $14M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.16% | $1.91 | $3.33 | +74.3% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDLN MEDLINE INC-CL A | 0.14% | $42.00 | $34.70 | -17.4% | $11.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DSGN DESIGN THERAPEUTICS INC | 0.14% | $8.78 | $12.57 | +43.2% | $18.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSP INSPIRE MEDICAL SYSTEMS INC | 0.13% | $77.64 | $138.72 | +78.7% | $19.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.12% | $9.50 | $15.33 | +61.4% | $10.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RANI RANI THERAPEUTICS HOLDINGS-A | 0.12% | $1.35 | $0.79 | -41.4% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 0.10% | $10.06 | $10.88 | +8.2% | $8.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACET ADICET BIO INC | 0.08% | $8.42 | $7.14 | -15.2% | $6.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMSW NEWAMSTERDAM PHARMA CO NV-27 | 0.08% | $0.87 | $12.65 | +1,356.9% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WGS GENEDX HOLDINGS CORP | 0.08% | $92.31 | $144.60 | +56.6% | $8.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WAY WAYSTAR HOLDING CORP | 0.05% | $32.75 | $25.34 | -22.6% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HOWL WEREWOLF THERAPEUTICS INC | 0.04% | $12.01 | $0.92 | -92.3% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HNGE HINGE HEALTH INC-A | 0.04% | $46.45 | $97.24 | +109.3% | $7.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PGNY PROGYNY INC | 0.03% | $21.52 | $25.19 | +17.1% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
N72482206 QIAGEN N.V. | 0.02% | $47.34 | $47.34 | 0.0% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KIDS ORTHOPEDIATRICS CORP | 0.02% | $17.76 | $19.13 | +7.7% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HCAT HEALTH CATALYST INC | 0.02% | $2.39 | $1.27 | -46.9% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTN PALATIN TECHNOLOGIES INC | 0.01% | $15.38 | $8.87 | -42.3% | $620.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
SEC filings for Q4 2025
- 13F-HR 0001104659-26-016482 · accepted Feb 17, 2026, 21:30 UTC